ClinicalTrials.gg
Enrolling by invitationNCT06384183ISACODUpdated Nov 13, 2026

Kerecis Real-World Fish Skin Graft Registry

An observational study in Wounds, Pressure Ulcer and Diabetic Foot Ulcer, sponsored by Kerecis Ltd.. Enrolling by invitation at 5 sites in United States. Per ClinicalTrials.gov, last updated 2026-11-13.

Primary conditionSurgical WoundRegistry: Wounds and InjuriesReclassifiedWhy we changed it
Registry
Wounds and Injuries — the first condition term the registry derived for this study.
ClinicalTrials.gg
Surgical Wound
Why
  1. The study's listed conditions name Surgical Wound, a narrower term within Wounds and Injuries.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Kerecis Ltd. (part of Coloplast A/S) · Observational

How we know

Updated Nov 13, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Other
Enrollment
600
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 130 studies in Surgical Wound with a site in United States — 18 open to participants now, 22 under way, none of them phase 3. Surgical Wound · United States.

Planned enrollment
Largest of 19
600 · median 48
Started
2024
with 5 others
Observational
19 of 130
5 open now
Primary completion
2026-12
later than 7 of 21 live
Registered
117th of 130
by date

Among the 130 studies in Surgical Wound with a site in United States, this one has the largest planned enrollment of the 19 observational ones that give a count, is one of 6 that started in 2024, is one of 19 observational ones, reaches primary completion later than 7 of the 21 other live ones, and was the 117th registered.

Surgical Wound

315 studies on the registry are indexed under Surgical Wound; 57 are open to participants now.

Browse Surgical Wound studies →

Open to participants now

18 of the 130 studies in Surgical Wound with a site in United States are open now. Recruiting first, the newest first:

12 more — sign in →

All 18 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 34 Surgical Wound studies recruiting now, 20 (59%) set no upper age limit and 10 (29%) stop at 75 or younger; 6 take children under 18; 7 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 130 studies in Surgical Wound with a site in United States, or all of them as a file.
02

Study summary

Multi-center, observational (i.e., non-interventional), open-label, real-world Registry on the Use of Kerecis Devices

Read the detailed description

This observational (i.e., non-interventional), post-market, real-world, Registry was designed to collect, analyze, and identify relevant safety and performance outcomes for "all comers" using Kerecis devices in routine medical practice within a wide variety of United States (US) medical practice settings. These clinical data will be used at Kerecis for many purposes, which include, but are not limited to, device safety and performance evaluation as part of routine patient care and post-market clinical follow-up data commitments to regulatory authorities around the world.

03

Conditions studied

  • Wounds
  • Pressure Ulcer
  • Diabetic Foot Ulcer
  • Venous Leg Ulcer
  • Surgical Wound
  • Soft Tissue Reinforcement
04

In context

Surgical Wound Reclassified

315 studies on the registry are indexed under Surgical Wound; 57 are open to participants now.

This study's planned enrollment of 600 is above the median of 72 across 51 observational studies indexed under Surgical Wound.

Browse Surgical Wound studies →

Lead sponsor

Kerecis Ltd. is the lead sponsor of 14 studies on the registry; 3 are open to participants now.

First submitted after Kerecis Ltd. became part of Coloplast A/S.

Compared within Surgical Wound, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Wounds and Injuries. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Investigators will only enter previously collected clinical data from patients (all ages, demographics, and any health status) who meet all inclusion criteria and no exclusion criteria.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provided
  • Has at least one target wound treated with a Kerecis device according to physician medical judgement within one calendar month prior to the registry enrollment date

Exclusion criteria

Exclusion Criteria:

  • None
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Observational model
Case-only
Time perspective
Other
Enrollment
600 participants (estimated)
Target follow-up
12 Months
Patient registry
Yes

Groups and cohorts

  • Observational Group

    This observational (i.e., non-interventional), post-market, real-world, Registry was designed to collect, analyze, and identify relevant safety and performance outcomes for "all comers" using Kerecis devices in routine medical practice within a wide variety of United States (US) medical practice settings.

    Device: Kerecis Fish Skin Graft

Interventions

  • DeviceKerecis Fish Skin Graft

    Patients already treated with a Kerecis device

07

What researchers measure

Primary outcomes

  1. Fish Skin Graft Device Related failure

    Proportion of patients with Kerecis FSG device-related failure for any reason (e.g., resulting in non-absorption or device removal)

    Time frame: 12 months

  2. Fish Skin Graft Device related allergy

    Proportion of patients with Kerecis FSG device-related allergy, hypersensitivity and/or autoimmune reaction (with or without documented auto-antibody development)

    Time frame: 12 months

  3. Target Wound Infection

    Proportion of patients who develop target wound infection

    Time frame: 12 months

Secondary outcomes

  1. Complete Wound Healing

    The Time in weeks to complete healing

    Time frame: 12 months

  2. Complete Wound Closure

    Proportion of participants who experience complete wound closure

    Time frame: 12 months

08

Study locations

5 sites
  • University Park
    Sarasota, Florida 34243, United States
  • Cone Health Ortho Care Greensboro
    Greensboro, North Carolina 27401, United States
  • Feet First Institute of Beavercreek
    Beavercreek, Ohio 45432, United States
  • ABC Podiatry
    Columbus, Ohio 43213, United States
  • South Texas Skin Cancer Center
    San Antonio, Texas 78215, United States
09

References and documents

Individual participant data

Plan to share: Undecided — To be determined

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Dec 2026, 28 months after the start.

Of 32 observational studies under Surgical Wound, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 143. This study's planned 28 months is above that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 13, 2026: primary completion Jun 2026 → Dec 2026 and completion Jun 2027 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2024
First posted
Apr 25, 2024
StartActual
Aug 7, 2024
Primary completionEst.
Dec 2026was Jun 2026
CompletionEst.
Dec 2027was Jun 2027
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site removed
Show 1 removed
  • MCR Health · Sarasota, United States
Nov 13, 2026
Primary completion
Jun 2026→Dec 2026
Nov 13, 2026
Study completion
Jun 2027→Dec 2027
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    1 site removed
    Show 1 removed
    • MCR Health · Sarasota, United States
    Primary completion Jun 2026→Dec 2026
    Study completion Jun 2027→Dec 2027
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06384183
Lead sponsor
Kerecis Ltd.
Responsible party
Sponsor
First posted
Apr 25, 2024
Start date
Aug 7, 2024
Primary completion
Dec 2026 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 13, 2026

Study contacts

Gunnar Johannsson
study director · Kerecis Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion